The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 479-482

  Savic, Aleksandar ^a   Kvrgic, Vanja ^a   Rajic, Nebojsa ^a   Urosevic, Ivana ^a   Kovacevic, Dragan ^b   Percic, Ivanka ^a   Popovic, Stevan ^a  

^a CLINICAL CENTER OF VOJVODINA   (Serbia)

^b Institute of Cardiovascular Diseases of Vojvodina   (Serbia)

Author keywords

Acute myeloid leukemia; Comorbidity; Early death; Overall survival

Indexed keywords

AMSACRINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84857231322     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.021     Document Type: Article

References (8)

1. Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
2. Giles F.J., Borthakur G., Ravandi F., Faderl S., Verstovsek S., Thomas D., et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007, 136:624-627.
3. Djunic I., Virijevic M., Novkovic A., Djurasinovic V., Colovic N., Vidovic A., et al. Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. Med Oncol 2011, [Epub ahead of print, February 18].
4. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
5. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:219-228.
6. O'Donnell M.R., Abboud C.N., Altman J., Appelbaum F.R., Coutre S.E., Damon L.E., et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2011, 9:280-317.
7. Juliusson G., Antunovic P., Derolf A., Lehmann S., Möllgård L., Stockelberg D., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
8. Marbello L., Ricci F., Nosari A.M., Turrini M., Nador G., Nichelatti M., et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res 2008, 32:1221-1227.